Cancer Research and Treatment

Case Report

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation: Sehhoon Park, Bo Mi Ku, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Se-Hoon Lee, Keunchil Park, Myung-Ju Ahn; Cancer Res Treat. 2020;52(4):1288-1290. Published online June 22, 2020; DOI: https://doi.org/10.4143/crt.2020.278

The non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutation eventually acquires resistant to either first or second-generation EGFR tyrosine kinase inhibitor (TKI). As the following option, targeting EGFR T790M with third-generation EGFR TKI is now established as a standard treatment option. In this study, we are reporting the first case of resistance mechanism to the novel third-generation EGFR TKI, lazertinib, which showed promising clinical efficacy in phase 1-2 study. The patients showed resistance to the treatment by acquiring the additional EGFR C797S mutation in cis which is also confirmed from the patient-derived cell lines.

Citations

Citations to this article as recorded by

Structural Studies of Fourth-Generation EGFR Inhibitors Reveal Insights into Selective T790M and C797S Targeting
Tahereh Damghani, Shenghan Song, Kaly S. Lin, Jianing Li, David E. Heppner
ACS Medicinal Chemistry Letters.2026; 17(2): 531. CrossRef
Epidermal Growth Factor Receptor as a Model Drug Target for Scrutinizing the Status Quo in Drug Discovery and Chemical Biology
David E. Heppner, Monica R. MacDonald, Nader N. Nasief, Shilpa E. Naik, Sahba Cunningham
ACS Bio & Med Chem Au.2026; 6(4): 293. CrossRef
Emerging Anti-Cancer and Repurposed Therapies for Overcoming Multidrug Resistance in Lung Cancer
Nilay Solanki, Pratham Shah, Sargam Kewalramani, Umang Shah, Mehul Patel, Swayamprakash Patel, Rajesh Maheshwari
Medical Oncology.2025;[Epub] CrossRef
Research Advances of Small Molecule EGFR-TKIs in NSCLC
亚南胡
Pharmacy Information.2024; 13(01): 1. CrossRef
An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief review
Prasad Sanjay Dhiwar, Gurubasavaraja Swamy Purawarga Matada, Rohit Pal, Ekta Singh, Abhishek Ghara, Lalmohan Maji, Sindhuja Sengupta, Ganesh Andhale
Journal of Biomolecular Structure and Dynamics.2024; 42(3): 1564. CrossRef
The efficacy of almonertinib and anlotinib combination therapy for advanced non‐small‐cell lung cancer patients who continued to experience cancer progression during third‐generation EGFR‐TKI treatment: a retrospective study
Yu Zhang, Chengmeng Wang, Jing Zhao, Meng Wang
Thoracic Cancer.2024; 15(23): 1757. CrossRef
Successful treatment of a patient with advanced lung adenocarcinoma (EGFR-T790M and C797S cis) with lazertinib: A case report and literature review
Yue Fang, Qiankun Zhang, Weimin Wang, Juanjuan Tong, Xialin Li
Frontiers in Oncology.2023;[Epub] CrossRef
A Review on Fused Pyrimidine Systems as EGFR Inhibitors and Their Structure–Activity Relationship
Tanuja T. Yadav, Gulam Moin Shaikh, Maushmi S. Kumar, Meena Chintamaneni, Mayur YC
Frontiers in Chemistry.2022;[Epub] CrossRef
Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)
David E. Heppner, Florian Wittlinger, Tyler S. Beyett, Tatiana Shaurova, Daniel A. Urul, Brian Buckley, Calvin D. Pham, Ilse K. Schaeffner, Bo Yang, Blessing C. Ogboo, Earl W. May, Erik M. Schaefer, Michael J. Eck, Stefan A. Laufer, Pamela A. Hershberger
ACS Medicinal Chemistry Letters.2022; 13(12): 1856. CrossRef
Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
Kyu Sic You, Yong Weon Yi, Jeonghee Cho, Jeong-Soo Park, Yeon-Sun Seong
Pharmaceuticals.2021; 14(6): 589. CrossRef
Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer
Sehhoon Park, Chung Lee, Bo Mi Ku, Minjae Kim, Woong-Yang Park, Nayoung K. D. Kim, Myung-Ju Ahn
BMB Reports.2021; 54(7): 386. CrossRef

11,953 View
364 Download
31 Web of Science
11 Crossref

Original Article

Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer: Min-Young Lee, Bo Mi Ku, Hae Su Kim, Ji Yun Lee, Sung Hee Lim, Jong-Mu Sun, Se-Hoon Lee, Keunchil Park, Young Lyun Oh, Mineui Hong, Han-Sin Jeong, Young-Ik Son, Chung-Hwan Baek, Myung-Ju Ahn; Cancer Res Treat. 2017;49(4):906-914. Published online December 26, 2016; DOI: https://doi.org/10.4143/crt.2016.424

Abstract PDF PubReader ePub

Purpose
Papillary thyroid carcinomas (PTCs) frequently involve genetic alterations. The objective of this study was to investigate genetic alterations and further explore the relationships between these genetic alterations and clinicopathological characteristics in a high-recurrence risk (node positive, N1) PTC group.
Materials and Methods
Tumor tissue blocks were obtained from 240 surgically resected patients with histologically confirmed stage III/IV (pT3/4 or N1) PTCs. We screened gene fusions using NanoString’s nCountertechnology and mutational analysiswas performed by directDNA sequencing.Data describing the clinicopathological characteristics and clinical courses were retrospectively collected.
Results
Of the 240 PTC patients, 207 (86.3%) had at least one genetic alteration, including BRAF mutation in 190 patients (79.2%), PIK3CA mutation in 25 patients (10.4%), NTRK1/3 fusion in six patients (2.5%), and RET fusion in 24 patients (10.0%). Concomitant presence of more than two genetic alterations was seen in 36 patients (15%). PTCs harboring BRAF mutation were associated with RET wild-type expression (p=0.001). RET fusion genes have been found to occur with significantly higher frequency in N1b stage patients (p=0.003) or groups of patients aged 45 years or older (p=0.031); however, no significant correlation was found between other genetic alterations. There was no trend toward favorable recurrence-free survival or overall survival among patients lacking genetic alterations.
Conclusion
In the selected high-recurrence risk PTC group, most patients had more than one genetic alteration. However, these known alterations could not entirely account for clinicopathological features of high-recurrence risk PTC.

Citations

Citations to this article as recorded by

Protective TGFβ2/SMAD3 axis identified by TWAS in papillary thyroid cancer
Qinnan Zhang, Jiayu Tang, Ju Yang, Yujin Li, Xueqing Li, Kangan Wang, Panpan Zhang, Kai Wang, Bingbing Zha
Endocrine-Related Cancer.2026;[Epub] CrossRef
Role of contrast-enhanced ultrasound with time-intensity curve analysis about thyroid nodule and parenchyma for differentiating BRAF V600E mutation status
Zhipeng Hu, Rong Xue, Zhixi Liu, Liang Liu, Zheli Gong
PeerJ.2025; 13: e19006. CrossRef
miR-7-5p and Importin-7 Regulate the p53 Dynamics and Stability in Malignant and Benign Thyroid Cells
Abeer Al-Abdallah, Iman Jahanbani, Bashayer Al-Shammari
International Journal of Molecular Sciences.2025; 26(12): 5813. CrossRef
BRAF V600E mutation co-existing with oncogenic mutations is associated with aggressive clinicopathologic features and poor prognosis in papillary thyroid carcinoma
Nobuyuki Bandoh, Takashi Goto, Yasutaka Kato, Akinobu Kubota, Shota Sakaue, Ryuhei Takeda, Shuto Hayashi, Misaki Hayashi, Shogo Baba, Tomomi Yamaguchi-Isochi, Hiroshi Nishihara, Hajime Kamada
Asian Journal of Surgery.2024; 47(1): 413. CrossRef
FHL1: A novel diagnostic marker for papillary thyroid carcinoma
Yeting Zeng, Dehua Zeng, Xingfeng Qi, Hanxi Wang, Xuzhou Wang, Xiaodong Dai, Lijuan Qu
Pathology International.2024; 74(9): 520. CrossRef
Rearranged During Transfection Rearrangement Detection by Fluorescence In Situ Hybridization Compared With Other Techniques in NSCLC
Anne Mc Leer, Julie Mondet, Nelly Magnat, Mailys Mersch, Diane Giovannini, Camille Emprou, Anne-Claire Toffart, Nathalie Sturm, Sylvie Lantuéjoul, David Benito
JTO Clinical and Research Reports.2024; 5(12): 100714. CrossRef
Essential news for clinical practice—thyroid cancer
Barbara Kiesewetter, Ladislaia Wolff, Markus Raderer
memo - Magazine of European Medical Oncology.2023; 16(1): 47. CrossRef
A new paradigm for epidermal growth factor receptor expression exists in PTC and NIFTP regulated by microRNAs
Abeer Al-Abdallah, Iman Jahanbani, Rola H. Ali, Nabeel Al-Brahim, Jeena Prasanth, Bashayer Al-Shammary, Maie Al-Bader
Frontiers in Oncology.2023;[Epub] CrossRef
NanoString in the screening of genetic abnormalities associated with thyroid cancer
Elisabetta Macerola, Anello Marcello Poma, Fulvio Basolo
Seminars in Cancer Biology.2022; 79: 132. CrossRef
The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with RET alterations
Steve Duff, Francesca Bargiacchi, Chelsea Norregaard, Melanie Brener, Erin Sullivan
Journal of Managed Care & Specialty Pharmacy.2022; 28(2): 218. CrossRef
Thyroid cancer incidence disparities among ethnic Asian American populations, 1990–2014
Alice W. Lee, Roy A. Mendoza, Shehla Aman, Robert Hsu, Lihua Liu
Annals of Epidemiology.2022; 66: 28. CrossRef
Analytical Accuracy of RET Fusion Detection by Break-Apart Fluorescence In Situ Hybridization
Jessica A. Baker, Anthony N. Sireci, Narasimha Marella, Holly Kay Cannon, Tyler J. Marquart, Timothy R. Holzer, Leslie O'Neill Reising, Joel D. Cook, Sameera R. Wijayawardana, Juraj Bodo, Eric D. Hsi, Andrew E. Schade, Gerard J. Oakley
Archives of Pathology & Laboratory Medicine.2022; 146(3): 351. CrossRef
Intratumoral Genetic Heterogeneity in Papillary Thyroid Cancer: Occurrence and Clinical Significance
Laura Fugazzola, Marina Muzza, Gabriele Pogliaghi, Mario Vitale
Cancers.2020; 12(2): 383. CrossRef
The stress-activated protein kinase pathway and the expression of stanniocalcin-1 are regulated by miR-146b-5p in papillary thyroid carcinogenesis
Abeer Al-Abdallah, Iman Jahanbani, Heba Mehdawi, Rola H Ali, Nabeel Al-Brahim, Olusegun Mojiminiyi
Cancer Biology & Therapy.2020; 21(5): 412. CrossRef
Risk Stratification Using a Novel Genetic Classifier Including PLEKHS1 Promoter Mutations for Differentiated Thyroid Cancer with Distant Metastasis
Chan Kwon Jung, Seung-Hyun Jung, Sora Jeon, Young Mun Jeong, Yourha Kim, Sohee Lee, Ja-Seong Bae, Yeun-Jun Chung
Thyroid®.2020; 30(11): 1589. CrossRef
Prediction of cervical lymph node metastasis with contrast-enhanced ultrasound and association between presence of BRAFV600E and extrathyroidal extension in papillary thyroid carcinoma
Jia Zhan, Long-hui Zhang, Qing Yu, Chao-lun Li, Yue Chen, Wen-Ping Wang, Hong Ding
Therapeutic Advances in Medical Oncology.2020;[Epub] CrossRef
Clinical significance of eukaryotic translation initiation factor 5A2 in papillary thyroid cancer
Hongmei Zhang, Kejun Zhang, Liang Ning, Dong Chen, Fengyun Hao, Peng Li
Bioengineered.2020; 11(1): 1325. CrossRef
High Preponderance of BRAF V600E Mutation in Papillary Thyroid Carcinoma Among Filipinos: A Clinicopathologic Study
Gerard Anthony M. Espiritu, Joemari T. Malana, Arlie Jean Grace V. Dumasis, Daphne C. Ang
Journal of Global Oncology.2019; (5): 1. CrossRef
PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis
Ali Alqahtani, Hazem S. K. Ayesh, Hafez Halawani
Cancers.2019; 12(1): 93. CrossRef
Targeted next‑generation sequencing of cancer‑related genes in thyroid carcinoma: A single institution's experience
Nobuyuki Bandoh, Toshiaki Akahane, Takashi Goto, Michihisa Kono, Haruyuki Ichikawa, Takahiro Sawada, Tomomi Yamaguchi, Hiroshi Nakano, Yumiko Kawase, Yasutaka Kato, Hajime Kamada, Yasuaki Harabuchi, Kazuo Shimizu, Hiroshi Nishihara
Oncology Letters.2018;[Epub] CrossRef
Niclosamide induces apoptosis through mitochondrial intrinsic pathway and inhibits migration and invasion in human thyroid cancer in vitro
Kai Yu, Tingting Wang, Yujue Li, Chun Wang, Xia Wang, Mei Zhang, Yongmei Xie, Shuangqing Li, Zhenmei An, Tinghong Ye
Biomedicine & Pharmacotherapy.2017; 92: 403. CrossRef

14,256 View
375 Download
22 Web of Science
21 Crossref

First
Prev
Page of 1
Next
Last

Search